These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16221104)

  • 21. Compliance with objectives based on different guidelines (KDIGO/S.E.N.) and analysis of the individual variability of mineral metabolism in haemodialysis patients in the medium term.
    del Pozo-Fernández C; López-Menchero-Martínez R; Álvarez-Avellán L; Albero-Molina MD; Sánchez-Rodríguez L
    Nefrologia; 2013; 33(5):675-84. PubMed ID: 24089159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cinacalcet versus Parathyroidectomy in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation.
    Soliman AR; Maamoun HA; Soliman MA; Darwish H; Elbanna E
    Rom J Intern Med; 2016 Sep; 54(3):184-189. PubMed ID: 27658167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
    Dong BJ
    Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
    Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
    Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
    Shahapuni I; Mansour J; Harbouche L; Maouad B; Benyahia M; Rahmouni K; Oprisiu R; Bonne JF; Monge M; El Esper N; Presne C; Moriniere P; Choukroun G; Fournier A
    Semin Dial; 2005; 18(3):226-38. PubMed ID: 15934970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study.
    Komaba H; Fukagawa M;
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S44-9. PubMed ID: 19032527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism.
    Yousaf F; Charytan C
    Ren Fail; 2014 Feb; 36(1):131-8. PubMed ID: 24060145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tolerance and efficacy of a low dose of the calcimimetic agent cinacalcet in controlling moderate to severe secondary hyperparathyroidism in hemodialysis patients.
    Bashir SO; Omer HA; Aamer MA; Somialy R; Morsy MD
    Saudi J Kidney Dis Transpl; 2015 Nov; 26(6):1135-41. PubMed ID: 26586050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients.
    El-Shafey EM; Alsahow AE; Alsaran K; Sabry AA; Atia M
    Ther Apher Dial; 2011 Dec; 15(6):547-55. PubMed ID: 22107691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical experience with cinacalcet HCl.
    Ureña Torres P
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V27-33. PubMed ID: 15284357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calcimimetics in chronic kidney disease: evidence, opportunities and challenges.
    Evenepoel P
    Kidney Int; 2008 Aug; 74(3):265-75. PubMed ID: 18528328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland - the observational TRANSIT Study.
    Pronai W; Rosenkranz AR; Bock A; Klauser-Braun R; Jäger C; Pendl G; Hemetsberger M; Lhotta K
    Wien Klin Wochenschr; 2017 May; 129(9-10):317-328. PubMed ID: 28091752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Calcimimetics in the chronic kidney disease-mineral and bone disorder.
    Bover J; Aguilar A; Baas J; Reyes J; Lloret MJ; Farré N; Olaya M; Canal C; Marco H; Andrés E; Trinidad P; Ballarin J
    Int J Artif Organs; 2009 Feb; 32(2):108-21. PubMed ID: 19363783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan.
    Iseki K
    Expert Opin Pharmacother; 2008 Mar; 9(4):601-10. PubMed ID: 18312161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism.
    Colloton M; Shatzen E; Miller G; Stehman-Breen C; Wada M; Lacey D; Martin D
    Kidney Int; 2005 Feb; 67(2):467-76. PubMed ID: 15673294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of parathyroidectomy versus calcimimetics for secondary hyperparathyroidism and kidney transplantation: a propensity-matched analysis.
    Koh EY; van der Plas WY; Dulfer RR; Pol RA; Kruijff S; Rotmans JI; Appelman-Dijkstra N; Schepers A; de Borst MH; Hoorn EJ; van Ginhoven TM; Nieveen van Dijkum EJM; Vogt L; Engelsman AF;
    Langenbecks Arch Surg; 2020 Sep; 405(6):851-859. PubMed ID: 32778916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Challenges in the therapy of secondary hyperparathyroidism.
    Wood C; González EA; Martin KJ
    Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Kidney and bone update : the 5-year history and future of CKD-MBD. Parathyroidectomy for secondary hyperparathyroidism].
    Tominaga Y
    Clin Calcium; 2012 Jul; 22(7):1083-8. PubMed ID: 22750941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.
    Parfrey PS; Chertow GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Dehmel B; Trotman ML; Modafferi DM; Goodman WG
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4834-44. PubMed ID: 24108314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.